Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$3,869 Mln
P/E Ratio
4.5
P/B Ratio
8.53
Industry P/E
--
Debt to Equity
18.81
ROE
0.43 %
ROCE
9.58 %
Div. Yield
7.47 %
Book Value
1.83
EPS
3.35
CFO
$16,175.00 Mln
EBITDA
$16,741.00 Mln
Net Profit
$12,623.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Organon & Co. (OGN)
| 2.61 | -6.19 | 0.07 | -17.47 | -24.68 | -- | -- |
|
BSE Sensex*
| -5.65 | -3.07 | -9.18 | 0.22 | 9.95 | 17.63 | 9.82 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Organon & Co. (OGN)
| 3.44 | -48.37 | -8.28 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 121.91 | 5,825.03 | -- | -231.63 | |
| 32.97 | 6,198.26 | -- | 38.11 | |
| 56.01 | 5,802.66 | 44.72 | 23.56 | |
| 9.10 | 11,029.70 | -- | -3.24 |
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The... company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey. Address: 30 Hudson Street, Jersey City, NJ, United States, 07302 Read more
CEO & Director
Mr. Kevin Ali
Executive VP & CFO
Mr. Matthew M. Walsh C.F.A.
Headquarters
Jersey City, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Organon & Co (OGN) stood at $ 13,101 Mln as on 31-Dec-24
The share price of Organon & Co (OGN) is $15.00 (NYSE) as of 14-Mar-2025 16:10 EDT. Organon & Co (OGN) has given a return of -24.68% in the last 3 years.
Organon & Co (OGN) has a market capitalisation of $ 3,869 Mln as on 13-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Organon & Co (OGN) is 4.50 times as on 13-Mar-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Organon & Co (OGN) and enter the required number of quantities and click on buy to purchase the shares of Organon & Co (OGN).
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey. Address: 30 Hudson Street, Jersey City, NJ, United States, 07302
The CEO & director of Mr. Kevin Ali. is Organon & Co (OGN), and CFO & Sr. VP is Mr. Matthew M. Walsh C.F.A..
There is no promoter pledging in Organon & Co (OGN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,132
|
|
|
665
|
|
|
610
|
|
|
591
|
| Organon & Co. (OGN) | Ratios |
|---|---|
|
Return on equity(%)
|
429.85
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
13.49
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Organon & Co (OGN) was $864 Mln.
$-0.60
(
